Generics 76

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Dapagliflozin manufacturers

76 products found

Filters

76 products found

dapagliflozin

Oral solution 10 mg/5 ml - 100 ml; 150 ml

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Available for
Licensing with supply
Comments
Early stage
Manufacturer #8593
It is a private R&D and business development organization established in the 2000s, specializing in the design and development of new pharmaceutical products worldwide. They have an average of 5-6 new developments per year, an average of 8-10 DCPs per year, more than 60 dossier updates in the last 10 years, they have more than 3 valid and approved patent applications, and approximately 140 MAs worldwide.

Manufacturer usually replies in 2 days

dapagliflozin + metformin

Tablets, film coated 5 mg + 850 mg, 5 mg + 1000 mg, 10 mg + 850 mg, 10 mg + 1000 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Available for
Licensing with supply, Distribution only
Manufacturer #17046

It is one of the fastest-growing pharmaceutical firms and a top investor in Rx and Healthcare solutions. The company has been awarded several prizes for its performance and growing business units and has recently been characterized as one of the local economy gems. Based in Europe.

Manufacturer usually replies in 6 days

dapagliflozin

Tablets, film coated 5 mg, 10 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Available for
Licensing with supply, Distribution only
Manufacturer #17046

It is one of the fastest-growing pharmaceutical firms and a top investor in Rx and Healthcare solutions. The company has been awarded several prizes for its performance and growing business units and has recently been characterized as one of the local economy gems. Based in Europe.

Manufacturer usually replies in 6 days

dapagliflozin + metformin

Tablets, extended release (ER) 5 mg + 1000 mg, 10 mg + 1000 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #21467

Manufacturer usually replies in 4 days

dapagliflozin + metformin

Tablets, film coated 5 mg + 1000 mg, 5 mg + 850 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #21467

Manufacturer usually replies in 4 days

dapagliflozin

Tablets, film coated 5 mg, 10 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Comments
EU MA's Running
Manufacturer #21467

Manufacturer usually replies in 4 days

dapagliflozin + metformin

Tablets, film coated 5 mg + 850 mg, 5 mg + 1000 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Vietnam
Manufacturer #16163
As a result of a strategic agreement with a company delivering an attractive high-quality portfolio with European supply, it is a trustworthy B2B partner with more than 30 years of experience in the out-licensing business model. The organization is a reliable commercial partner that takes a customer-centric approach and strives for long-term partnership development to secure market success.

Manufacturer usually replies in 6 days

dapagliflozin

Tablets, film coated 5 mg, 10 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Vietnam , Iraq
Manufacturer #16163
As a result of a strategic agreement with a company delivering an attractive high-quality portfolio with European supply, it is a trustworthy B2B partner with more than 30 years of experience in the out-licensing business model. The organization is a reliable commercial partner that takes a customer-centric approach and strives for long-term partnership development to secure market success.

Manufacturer usually replies in 6 days

dapagliflozin + metformin

Tablets, film coated 5 mg + 850 mg, 5 mg + 1000 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Ref: Ebymect®/Xigduo®
Manufacturer #252

Manufacturer usually replies in 2 days

dapagliflozin

Tablets, film coated 5 mg, 10 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Ref: Edistride®/Forxiga®
Manufacturer #252

Manufacturer usually replies in 2 days

dapagliflozin

Tablets, film coated 5 mg, 10 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Dossier availability date: Q3 2024
Manufacturer #422

A pharmaceutical manufacturer based in the EU that has been active in 100+ countries selling its products in Europe, North America, Africa, the Middle East, and Asia for 40+ years. Main therapeutic areas include CNS, cardiovascular medication, and anti-infectives. The company's production lines are EU GMP-compliant. Key production lines are Rx and OTC. The company owns 20+ branches in Europe, Africa, and Asia.

Manufacturer usually replies in 5 days

dapagliflozin + metformin

Tablets, film coated 5 mg + 500 mg, 5 mg + 850 mg , 5 mg + 1000 mg , 10 mg + 500 mg, 10 mg + 1000 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Reference product: Xigduo
Manufacturer #19112
A pharmaceutical manufacturer based in the EU that develops and produces generic medicines and sells its products in the EU, North America, LATAM, and Africa. Main therapeutic areas include diabetes, urology, and antidepressant. The company possesses its own R&D and regulatory department.

Manufacturer usually replies in 7 days

dapagliflozin

Tablets, film coated 5mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #1250

Manufacturer usually replies in 7 days

dapagliflozin

Tablets, film coated 5 mg, 10 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Dossier availability date: Q4 2025
Manufacturer #519

Manufacturer usually replies in 6 days

dapagliflozin + metformin

Tablets, film coated 5 mg + 850 mg, 5 mg + 1000 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Dossier availability date: Q2 2026
Manufacturer #519

Manufacturer usually replies in 6 days

dapagliflozin

Tablets, film coated 5 mg, 10 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
RLD: Forxiga (Bristol - Myers Squibb/Astra Zeneca). Dossier availability date: Q3 2025
Manufacturer #19992
A pharmaceutical manufacturer based in the EU that is active in 20+ countries selling its products for 190+ years. Key production lines are Rx, OTC, medical devices, and nutraceuticals. The company's production lines are GMP-compliant. Main therapy areas include anti-infectives, dermatology, and CNS. The company products are prepared in CTD dossier format.

Manufacturer usually replies in 6 days

dapagliflozin + losartan

Tablets 5 mg + 850 mg, 5 mg + 1000 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #313

A pharmaceutical manufacturer based in the EU that has been active in 50+ countries selling its products in Europe, North America, LATAM, and Asia for 10+ years. Key production lines are Rx, OTC, and nutraceuticals. Main therapeutic areas include the respiratory system, dermatology, and cardiovascular system. The company possesses several branches in LATAM

Manufacturer usually replies in 7 days

dapagliflozin

Tablets 5 mg, 10 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Vietnam
Manufacturer #313

A pharmaceutical manufacturer based in the EU that has been active in 50+ countries selling its products in Europe, North America, LATAM, and Asia for 10+ years. Key production lines are Rx, OTC, and nutraceuticals. Main therapeutic areas include the respiratory system, dermatology, and cardiovascular system. The company possesses several branches in LATAM

Manufacturer usually replies in 7 days

dapagliflozin + losartan

Tablets, film coated 5 mg + 850 mg, 5 mg + 1000 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Ref: Ebymect
Manufacturer #15925
The global pharmaceutical manufacturer that deals with affordable but high-quality drugs that help in getting exceptional aftercare services in terms of pharmaceutical products. Their products are innovated and made at the lab and then completely tested so that the best results could be achieved.

Manufacturer usually replies in 8 days

dapagliflozin

Tablets, film coated 5 mg, 10 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Ref: Forxiga
Manufacturer #15925
The global pharmaceutical manufacturer that deals with affordable but high-quality drugs that help in getting exceptional aftercare services in terms of pharmaceutical products. Their products are innovated and made at the lab and then completely tested so that the best results could be achieved.

Manufacturer usually replies in 8 days

Want to view all 76 products? Create your free account today!

Dapagliflozin Manufacturers

Dapagliflozin is classified under sodium-glucose Co-transporter 2(SGLT2) inhibitors and sold under the brand names of Farxiga among many others. It is used to improve glycaemic control in adults having diabetes mellitus type 2. It is also used to decrease the risk of heart attack or stroke which is life-threatening in type 2 diabetic patients. It is contraindicated in those who are allergic to it, and patients with conditions like; renal problems, ketosis caused by diabetes (call your doctor for treatment). Talk with a doctor if experiencing these conditions, like polycystic kidney disease (PKD), hepatitis; Infections of the bladder or other urination problems, hypotension (low blood pressure), problems with your pancreas, which may require surgical intervention; if you are dehydrated; if you are a heavy drinker; or on a low-sodium diet. The most common side effects of this pharmaceutical medicine include a yeast infection of genitalia, frequent urination than usual, sore throat, runny/stuffy nose. A symptom of genital infection includes burning, itching, odor, discharge, tenderness, redness or swelling of the genital or rectal area, and fever. If side effects worsen, get doctor help immediately. This pharmaceutical medicine is administered through the oral route. It is not recommended during the second and third trimesters of pregnancy. Furthermore, it is categorized as pregnancy category ‘D’ Drugs. It is not recommended in breastfeeding women and data of secretion into human milk is yet unknown. Dapagliflozin was approved by the FDA to reduce the risk of decline in kidney function, renal failure, and cardiac failure of hospitalized adults with chronic kidney disease (CKD) who are at risk of disease progression. In individuals with type 2 diabetes, dapagliflozin is used in conjunction with exercise and diet, as well as other drugs, to lower blood sugar levels. This is taken to lower the chance of having to go to the clinic for heart problems in persons with type 2 diabetes, heart disease, and vascular disease, or who have numerous health risks for heart-related disease.

How does Dapagliflozin work?

Being a sodium-glucose cotransporter-2 inhibitor (SGLT2) it lowers sugar levels in the blood and removes it from the body by excreting in urine. The inactive 3-O-glucuronide metabolite of dapagliflozin is predominantly glucuronidated (60.7 percent ). Other small glucuronidated metabolites (5.4%), a de-ethylated metabolite (5%), and a hydroxylated metabolite (5%) are all produced by dapagliflozin. Cytochrome p-450(CYP)1A1, CYP1A2, CYP2A6, CYP2C9, CYP2D6, CYP3A4, uridine phosphatidyl glucuronyltransferase(UGT)1A9, UGT2B4, and UGT2B72 are involved in the metabolic of dapagliflozin. UGT1A9 is responsible for gluconeogenesis to the main enzyme. The salt cotransporter 2 (SGLT2), which is largely found in the proximal convoluted tubule of the nephron1, is inhibited by dapagliflozin. Because SGLT2 enables 90% of sugar resorption in the kidneys, inhibiting it permits glucose to be eliminated in the urine. In individuals with type 2 diabetes, this excretion makes for improved glycemic management and maybe losing weight. When people have been hungry, oral dapagliflozin achieves its maximal levels within 1 hour of administration. The duration to peak concentration increases to two hands the significant level reduces by half when patients ingest a high-fat meal, though no dose change is required. Dapagliflozin is 78 percent bioavailable when taken orally.

The Wholesale Price of Dapagliflozin

The wholesale price for 30 tablets of Dapagliflozin 5mg is approximately 565.79 dollars. Price may change from dealer to dealer. As for its wholesale pricing, you can order at anywhere from around $100 to $150 in the US. Dapagliflozin is available for sale from a variety of Dapagliflozin vendors at a range of costs. Prices are only valid for consumers who pay cash and do not apply to insurance coverage. Dapagliflozin suppliers, on the whole, are in favor of patient aid initiatives. Varying drugstores may have different prices.

Navigating Our Pharmaceutical Marketplace

Being a global B2B pharmaceutical online marketplace, Pipelinepharma is structured to simplify pharmaceutical deals by providing you with an intuitive interface that is easy to engage with. The selection of Dapagliflozin offerings can be narrowed down with the use of filters and easily weighed against one another according to medication prices and commercial terms. The advanced filters help you filter out the countries for Dapagliflozin manufacturers and Dapagliflozin suppliers that you are looking for. These also enable you to check the dossier status of Dapagliflozin, and the GMP approvals of the different variants of Dapagliflozin. Also, each manufacturer or supplier product description contains essential information about Dapagliflozin including clinical data, stability zones, countries where Dapagliflozin is already registered in. Manufacturers also have special, and delivery terms.

Establishing Commercial Ties

If you are a pharmaceutical licensing company or a distributor you can enter into deals or negotiations over Dapagliflozin offers with manufacturing companies after completing the free registration process and joining our online marketplace. This helps to ensure that you conclude the pharmaceutical deal at a reasonable cost and achieve the best cost/benefit ratio for your company while bypassing lengthy sourcing, negotiation, and order process. Once you have finalized a deal, you can look forward to a long-lasting business relationship with the manufacturers or suppliers. This way, the marketplace allows you as a distributor to skip the process of making a list of product manufacturers every time you are looking for in-licensing or distribution deals.

Quality Assurance

To keep up to the quality standards other than Good Manufacturing Practice approvals that Dapagliflozin manufacturers list has, we qualify their companies before they are boarded on the platform. This allows us to screen Dapagliflozin manufacturers for the quality of the pharmaceutical products’ dossiers and protect against the risk of possible malpractices.